2 October 2020
An interim clinical commissioning policy has been in place across the UK since 3 July 2020, defining routine access to remdesivir in the treatment of COVID-19 in adults and children aged 12 years or older. However, due to increased demand against available supply, clinicians are now asked to apply t...
9 September 2020
Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.
26 June 2020
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.
This new microsite is your essential resource on child protection and safeguarding - whether you are involved with child protection as a child health professional, allied health professional, social worker, solicitor or barrister.
17 March 2020
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
2 March 2020
The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.
5 February 2020
Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.
The Medicines and Healthcare products Regulatory Agency (MHRA) “Yellow Card Scheme” is the UK system for collecting and monitoring information on suspected safety concerns or incidents involving side effects to medicines (also known as adverse drug reactions or ADRs) and medical devices.
Experts from 13 national bodies, including seven Royal Colleges, joined forces in March 2019 to launch practical guidance to support doctors and other health professionals around the use of this medicine in women and girls in their reproductive years.
16 December 2019
Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg because of a lack of evidence for benefit.